Sun Pharma gets USFDA nod for prostate cancer drug

PTI New Delhi | Updated on May 23, 2018 Published on May 23, 2018

Sun Pharmaceutical Industries’ subsidiary has received approval from the US health regulator for YONSA, used for the treatment of a form of prostate cancer.

In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said: “One of Sun Pharma’s wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA) for YONSA.”

YONSA (abiraterone acetate) in combination with methylprednisolone is a novel formulation for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the company said.

Sun Pharma said Churchill is eligible to receive upfront and sales-linked milestone payments as well as royalties on sales pursuant to an agreement between the two companies to commercialise YONSA in the US.

YONSA in combination with methylprednisolone has been filed as a new drug application (NDA) and will be promoted as a branded product in the US, Sun Pharma added.

Shares of Sun Pharma were trading 1.49 per cent higher at Rs 459.75 apiece on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 23, 2018
This article is closed for comments.
Please Email the Editor